BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND CALCB, Calcitonin AND Treatment
438 results:

  • 1. Hsp70 and calcitonin Receptor Protein in Extracellular Vesicles from Glioblastoma Multiforme: Biomarkers with Putative Roles in Carcinogenesis and Potential for Differentiating tumor Types.
    Alberti G; Sánchez-López CM; Marcilla A; Barone R; Caruso Bavisotto C; Graziano F; Conway de Macario E; Macario AJL; Bucchieri F; Cappello F; Campanella C; Rappa F
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542389
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Extent of Surgery for Medullary Thyroid Cancer and Prevalence of Occult Contralateral Foci.
    Mao YV; Hughes EG; Steinmetz D; Troob S; Kim J; Tseng CH; Fishbein GA; Sajed DP; Livhits MJ; Yeh MW; Lee D; Angell TE; Wu JX
    JAMA Otolaryngol Head Neck Surg; 2024 Mar; 150(3):209-214. PubMed ID: 38270925
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Precision medicine in endocrinology exemplified by medullary thyroid cancer].
    Brandenburg T; Machlah YM; Führer D
    Inn Med (Heidelb); 2024 Mar; 65(3):202-210. PubMed ID: 38231404
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Individualization of treatment in sporadic and hereditary medullary thyroid cancer].
    Lorenz K; Machens A; Dralle H
    Chirurgie (Heidelb); 2024 Mar; 95(3):186-191. PubMed ID: 38214736
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Risk factors for cervical lymph node metastasis in the central or lateral cervical region in medullary thyroid carcinoma: a systematic review and meta-analysis.
    Lin X; Huo J; Su H; Zhu C; Xu Y; Zhang F
    Eur Arch Otorhinolaryngol; 2024 Feb; 281(2):547-561. PubMed ID: 37801162
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report.
    Behdadnia A; Jeddi M
    J Med Case Rep; 2023 Sep; 17(1):400. PubMed ID: 37670372
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. CD276 as a Candidate Target for Immunotherapy in Medullary Thyroid Cancer.
    Hińcza-Nowak K; Kowalik A; Walczyk A; Pałyga I; Gąsior-Perczak D; Płusa A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373167
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Radioactive iodine in the management of medullary carcinoma of the thyroid.
    Rowell NP
    Br J Radiol; 2023 Aug; 96(1148):20220660. PubMed ID: 37335288
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Medullary Thyroid Cancer: Updates and Challenges.
    Gild ML; Clifton-Bligh RJ; Wirth LJ; Robinson BG
    Endocr Rev; 2023 Sep; 44(5):934-946. PubMed ID: 37204852
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma.
    Kesby N; Mechera R; Fuchs T; Papachristos A; Gild M; Tsang V; Clifton-Bligh R; Robinson B; Sywak M; Sidhu S; Chou A; Gill AJ; Glover A
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2626-2634. PubMed ID: 36964913
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Clinical Evolution of Sporadic Medullary Thyroid Carcinoma With Biochemical Incomplete Response After Initial treatment.
    Prete A; Gambale C; Torregrossa L; Ciampi R; Romei C; Ramone T; Agate L; Bottici V; Cappagli V; Molinaro E; Materazzi G; Elisei R; Matrone A
    J Clin Endocrinol Metab; 2023 Jul; 108(8):e613-e622. PubMed ID: 36722192
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine.
    Treglia G; Rufini V; Piccardo A; Imperiale A
    Semin Nucl Med; 2023 Jul; 53(4):481-489. PubMed ID: 36702731
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Other markers of medullary thyroid cancer, not only calcitonin.
    Censi S; Manso J; Mian C
    Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651167
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Risk factors of recurrence or metastasis in patients with medullary thyroid carcinoma].
    Guo FL; Li LJ; Ruan XH; Fu GM; Zhao JZ; Hou XK; Gao M; Zheng XQ
    Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3849-3855. PubMed ID: 36540922
    [No Abstract]    [Full Text] [Related]  

  • 15. Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma.
    Yue W; Zhang Y
    Front Endocrinol (Lausanne); 2022; 13():1025629. PubMed ID: 36506082
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Lobectomy may be more appropriate for patients with early-stage medullary thyroid cancer older than 60 years old.
    Yang B; Niu G; Li X; Ma F; Ma Y; Hu S
    Front Endocrinol (Lausanne); 2022; 13():1015319. PubMed ID: 36339396
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.
    Dadgar H; Jafari E; Ahmadzadehfar H; Rekabpour SJ; Ravanbod MR; Kalantarhormozi M; Nabipour I; Assadi M
    Ann Endocrinol (Paris); 2023 Feb; 84(1):45-51. PubMed ID: 36126757
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A Rare Case of Negative Serum calcitonin in Metastatic Medullary Thyroid Carcinoma: Diagnosis, treatment, and Follow-Up Strategy.
    Licata L; Di Fidio CA; Vacante M; Basile F; Biondi A; Richiusa P; Gurrera A; Ciuni R
    Am J Case Rep; 2022 Sep; 23():e935207. PubMed ID: 36088532
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. RREB1 promotes the development of parafollicular carcinogenesis through the Ras-Raf-1-ELK3 signaling pathway.
    Ma S; Wang H; Li W; Yan Z; Luo X; Lu P
    Nucleosides Nucleotides Nucleic Acids; 2022; 41(10):972-981. PubMed ID: 35737446
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Medullary thyroid carcinoma: a narrative historical review.
    Wong A; Nabata K; Wiseman SM
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):823-834. PubMed ID: 35694971
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 22.